ABSTRACT: The use of fluoroquinolones (FQs) to treat lower respiratory tract infections (LTRI) other than tuberculosis (TB) allows selection of FQ-resistant TB when TB is misdiagnosed. This study maps national guidelines on the use of FQs for LRTI in Europe and determines the risk of FQ-resistant TB upon FQ treatment before TB diagnosis.
T he rational use of antibiotics has recently attracted major attention, being selected as the topic of the 2011 World Health Day [1] [2] [3] . Drug resistant tuberculosis (TB) is a growing threat to the control and ultimate elimination of TB [4] [5] [6] [7] . Not only has multidrug-resistant (MDR)-TB [8, 9] established itself within the European Union (EU) borders, but extensively drug-resistant (XDR)-TB [10, 11] has also become an issue. More recently, debate was initiated to define as extremely drugresistant (XXDR)-TB or total drug resistant (TDR)-TB, TB cases that harbour Mycobacterium tuberculosis strains with resistance to all the known drugs [12] [13] [14] . The World Health Organization (WHO) has initiated discussions on the eventual need to develop a definition for such resistant TB strains. At present, however, an international, expert-endorsed definition has not yet been agreed.
Drug resistance in M. tuberculosis occurs through spontaneous chromosomal mutations [15, 16] and, depending on the drug target, resistance to a specific drug occurs at a specific rate (i.e. every x number of bacilli will have a mutation conferring resistance to a specific drug). This in itself forms the basis and rationale for multi-drug TB regimens, targeting the bacilli from several angles to ensure all bacilli are killed.
Recent research has shown that the use of fluoroquinolones (FQs), one of the key second-line drugs for the treatment of MDR-TB [17] [18] [19] [20] [21] [22] also used to treat other lower respiratory tract infections (LRTIs), poses a potential risk for selecting FQ-resistant strains of M. tuberculosis in case TB disease is misdiagnosed.
The EU is a heterogeneous setting with regard to TB incidence, with several member states having a low-incidence of the disease [23, 24] . This in itself presents the possibility that TB diagnosis is not considered when patients present with a persistent cough, and that patients may be erroneously treated for another LRTI. Being a broad-spectrum antibiotic effective against several respiratory infections, FQs can be a choice of treatment for such infections. There is, in other words, the risk of selecting FQ-resistant strains (regardless of resistance pattern to other drugs) if FQs are used in LRTI without the prior exclusion of TB disease.
In this manuscript, we aimed to: 1) assess recommendations on FQ use for LRTIs other than TB by mapping existing national guidelines for the treatment of LRTI/community-acquired pneumonia (CAP) in EU/European Economic Area (EEA) member states; and 2) assess whether treatment with FQs before the diagnosis of TB is associated with a higher risk of FQ-resistant TB.
DEFINITIONS
World Health Organization (WHO): the United Nations agency directing and coordinating public health priorities.
European Centre for Disease Prevention and Control (ECDC):
EU agency mandated to identify, assess and communicate current and emerging threats to human health posed by infectious diseases. The ECDC is located in Stockholm, Sweden.
European Respiratory Society (ERS): one of the leading scientific societies focused on respiratory medicine. TB: defined as the clinical, bacteriological and/or radiographical manifest disease [6, 18, 25] .
MDR-TB: TB caused by M. tuberculosis strains resistant to at least the two first-line anti-TB drugs, isoniazid (INH) and rifampicin (RMP) [11] . XDR-TB: TB caused by M. tuberculosis resistant to RMP and INH (i.e. MDR-TB) plus any FQ, and at least one of the three following injectable drugs: capreomycin, kanamycin or amikacin [11] . XXDR-TB: M. tuberculosis strains resistant to all available firstand second-line drugs. Of note, there is currently no internationally endorsed definition of XXDR-TB. A definition of TB cases resistant to all TB drugs is currently being discussed and WHO is in the process of assessing the need to develop an official definition [12] [13] [14] .
TDR-TB: M. tuberculosis strains resistant to all first-and secondline drugs tested. Of note, there is currently no internationally endorsed definition of TDR-TB, this is a definition proposed by authors based on a recent publication [12] . A definition of TB cases resistant to all TB drugs is currently being discussed and WHO is in the process of assessing the need to develop an official definition [12, 26] .
Low TB incidence country: countries with a crude notification rate ,20 per 100,000 population [7, 24] .
LRTI: an acute illness (present for f21 days) usually with cough as the main symptom, with at least one other lower respiratory tract symptom (sputum production, dyspnoea, wheeze or chest discomfort/pain) and no alternative explanation (e.g. sinusitis or asthma).
Suspected CAP: an acute illness with cough and at least one of new focal chest signs, fever for .4 days or dyspnoea/ tachypnoea, and without other obvious cause [21, 22] .
Definite CAP: as for suspected CAP, but supported by chest radiograph findings of lung shadowing that is likely to be new. In the elderly, the presence of shadowing on a chest radiograph accompanied by acute clinical illness (unspecified) without other obvious cause.
TB control: strategies aimed to reduce the incidence of new infections with M. tuberculosis complex by identifying sources of infection as rapidly as possible and rendering them noninfectious through curative treatment. Currently, non-infectious cases are also a priority for TB control to reduce human suffering, including in children [27] .
TB elimination: the point at which less than one case per 1,000,000 inhabitants emerges annually in the general population [7, 24, 28] .
Practical Approach to Lung Health (PAL): this is a WHOlaunched programme aimed at integrating the clinical and public health approach to respiratory symptoms and diseases [29] .
METHODS
Assessing recommendations on the use of FQ in the EU for LRTI other than TB by mapping existing national guidelines for the treatment of LRTI/CAP A questionnaire was developed by the ECDC in collaboration with the ERS and aimed at: 1) mapping the existing national guidelines for the management of LTRI and CAP; 2) assessing the extent to which FQs are recommended for the treatment of LRTIs other than TB and availability of information on the risk of TB patients developing FQ resistance if misdiagnosed with another LRTI and treated with FQs; and 3) assessing whether the subsequent recommendations on the use of FQs for treatment included the need to exclude TB prior to treatment.
The questionnaire was divided into two sections and consisted of 10 questions with a yes/no answer investigating the guidelines on LRTI and CAP (table 1). The questionnaire was sent by the ERS (Lausanne, Switzerland) to 30 ERS national delegates belonging to the EU/EEA member states. A reminder was sent to the late respondents 15 days after the first invitation. In case of no response, the questionnaires from these countries were received by collaboration of the ERS officers in these countries, in order to achieve a satisfactory response rate (80%).
Estimating the risk for FQ-resistant TB if treated with FQ prior to TB diagnosis A systematic review to assess the association between the use of FQs for CAP and other respiratory infections and FQ-resistant TB had been recently performed by CHEN et al. [30] . We assessed the quality of the systematic review with the AMSTAR checklist [31] and concluded that the review by CHEN et al. [30] was well performed. However, the risk of bias of the included studies was not assessed by the authors [30] . We decided to update the results and to assess the risk of bias of the included studies.
For the update, we searched the literature (January 1, 2010 to January 18, 2011) for relevant studies. Compared with CHEN et al. [30] , our search strategy included more keywords and MeSH terms (Annex 1 in supplementary material). We did not search CINAHL [32] as this database was unlikely to provide any relevant papers. We did search the TRIP database [33] . Ongoing randomised control trials on FQs (which might report on adverse effects) were searched via the WHO International Clinical Trials Registry Platform [34] .
For the updated search, one investigator selected studies for eligibility. A 10% random sample was assessed by a second investigator and compared with the assessment of the first investigator. If there had been relevant inconsistencies all articles would have been evaluated by the second author. One investigator extracted all relevant data items from the included studies. A second investigator independently extracted the main results of the included studies and checked the extract of a subsample of the articles. Consensus was reached by discussion. The meta-analysis was performed as stated by CHEN et al. [30] . Two investigators independently assessed the risk of bias of the included studies using the Newcastle Ottawa Scale (NOS) for cohort studies [35] .
RESULTS
Assessing recommendations on the use of FQ in the EU for LRTI other than TB by mapping national guidelines for the treatment of LRTI/CAP 24 (80%) out of 30 national delegates from the following countries responded to the questionnaire: Austria, Belgium, Bulgaria, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, UK.
At the time of the survey, 15 (62%) of the 24 responding national delegates had national/sub-national guidelines for the management of LRTIs, of which seven (47%) included recommendations on the differential diagnosis, treatment and management of TB and seven the recommendation on the use of FQs in LTRI and the risk of FQ-resistant TB in misdiagnosed patients. Only one of the 15 guidelines recommended FQs as the first drug of choice to treat LRTIs and 10 (67%) recommended their use as a second drug of choice.
18 (75%) out of the 24 responding national delegates reported having national/sub-national guidelines specifically for the management of CAP at the time of the survey, of which, seven (39%) included recommendations on the differential diagnosis, treatment and management of TB and seven the recommendation on the use of FQs in CAP and the risk of FQ-resistant TB in misdiagnosed patients. Only two of the 18 guidelines recommended FQs as the first drug of choice to treat CAP and 12 (67%) recommended their use as a second drug of choice. The detailed results are summarised in table 2.
Estimating the risk for FQ-resistant TB if treated with FQ prior to TB diagnosis Search results in the update The update of the search identified 192 records; one study was eligible for inclusion [36] . In total, up to January 18, 2011, six studies investigating FQ exposure and the risk of FQ-resistant TB were included [36] [37] [38] [39] [40] [41] . The most recently published study PERSPECTIVE: PROTECTING THE TB DRUG PIPELINE G.B. MIGLIORI ET AL.
[36] provided an overview of all relevant studies, and these include the same studies as in the review by CHEN et al [30] .
Description of the included studies Table 3 summarises the characteristics of the included studies. The exposure period, i.e. the period in which FQ exposure (through prescription) was measured, varied between 100 days and 12 months before TB diagnosis. One study did not report this period [39] . The proportion of TB cases exposed to FQs prior to TB diagnosis varied between 1.4% and 35%.
Risk of bias assessment
The NOS star template in table 4 presents the results of the risk of bias assessment. It cannot be ruled out that, for all studies, the outcome of interest (e.g. FQ resistance) was already present at the time of exposure. For FQ-exposed patients this might be the case, as it is possible that FQ were prescribed for symptoms actually due to TB sustained by M. tuberculosis strains already resistant to FQ (but wrongly assumed to be caused by CAP). This may result in an overestimation of the association between FQ-exposure and FQ-resistant TB.
Three studies were adjusted for confounders [36, 40, 41] . Although the other included studies did not adjust for confounders, no baseline differences likely to be associated to FQ resistance were found and comparability was considered possible.
Other potential sources of bias we assessed were representativeness [36] , selective inclusion [36, 37] and incomplete outcome assessment [36, 38, 41] . In all the studies analysed, quality was scored as moderate to high. As all studies are retrospective, data on FQ use may have been underestimated. However, this misclassification is likely to be similar for FQresistant and FQ-susceptible TB patients. Figure 1 presents the updated meta-analysis results. TB patients had a 2.81 (95% CI 1.47-5.39) higher risk of FQ-resistant TB when they had been prescribed FQs before TB diagnosis than TB patients not exposed to FQs. The first aim of this review was to assess existing recommendations on the use of FQs in the EU for LRTIs other than TB by mapping existing national guidelines for the treatment of LRTI/ CAP. At the time of the survey, not all national guidelines on LTRI and/or CAP highlighted the need to consider differential diagnosis of TB. Furthermore, among existing LRTI and CAP guidelines only seven informed on the potential risk of developing FQ resistance in misdiagnosed TB patients. In the EU setting, composed of numerous low-incidence countries where medical doctors have little opportunity to investigate a TB patient, there is a real risk that TB is not considered when a coughing patient reports to healthcare services. Maintaining the ''know-how'' on TB, e.g. ensuring that TB patients are correctly diagnosed, is essential to stop disease transmission in the population and further prevent drug resistance development [18, 24, 25, 29] . Accessing clinicians through guidelines is a key channel to maintain know-how and keep TB high on the clinical agenda. Updating national and sub-national guidelines for the treatment of LRTI and CAP is therefore warranted, as well as describing the need for TB differential diagnosis and the risks behind FQs.
Data synthesis
The recommendations included in national guidelines should be in line with PAL [29] and the International Standards for TB Care [25] . The recently launched EU Standards for TB Care [18] offer a further source to tailor TB standards to the EU. A reassuring finding was that 10 LRTI guidelines and 12 CAP guidelines only recommended FQs as the second drug of choice for treatment, indicating the prudent use of this broadspectrum antibiotic.
The second aim of this review was to assess whether treatment with FQs before TB diagnosis is associated with a higher risk of FQ-resistant TB. All studies started by identifying patients with culture-confirmed TB and measured FQ resistance in these patients. FQ exposure was assessed by linkage with medical records or pharmacy registers.
In total, six studies of moderate-to-high quality were included. TB patients had a three-fold higher risk of FQ-resistant TB when they had been prescribed FQs before TB diagnosis, compared to TB patients who were not exposed to FQs (OR 2.81, 95% CI 1.47-5.39). This is comparable to the OR of 2.7 reported by CHEN et al. [30] .
The presence of FQ resistance at the time of FQ exposure would give an overestimation of the association between FQ exposure and FQ resistance. The risk of bias is high if pre-existing FQ resistance is related to exposure status. In this review we found some indirect evidence for this hypothesis: four out of the six studies included re-treatment cases, which is associated with drug resistance [44] . Moreover, the study of JEON et al. [36] showed a higher percentage of re-treatment cases among the FQexposed patients (table 2) . WANG et al. [39] found a higher level of FQ resistance among the re-treatment cases: 7.9% versus 2.5%.
The aim was to investigate FQ prescription for CAP or other respiratory infections. However, FQ were prescribed for other indications as well. It seems unlikely that this has an effect on the mechanism of development of FQ resistance. However, if FQs are prescribed for indications other than CAP it is less likely that the symptoms for which it was described were actually due to undiagnosed pulmonary TB. In these cases, monotherapy with FQs cannot be considered inappropriate and intensifying the diagnostic process by excluding TB before prescribing FQs does not seem relevant.
A recently published study by ADRIAENSSENS et al. [45] reports on the European outpatient use of FQs and offers several elements for a fruitful integration with the data generated by our study. Data on more than a decade of outpatient quinolone use were collected within the European Surveillance of Antimicrobial Consumption project, funded by ECDC [45] .
Earlier FQs (including ofloxacin, levofloxacin and, particularly, ciprofloxacin) were seen to be the most frequently used in the 33 The authors conclude that the overall increase in FQ prescription reflects the shift from the earlier FQs (aimed at treating urinary tract infections) to the newer, more recent ''respiratory'' G.B. MIGLIORI ET AL. PERSPECTIVE: PROTECTING THE TB DRUG PIPELINE c quinolones. They further note concern for the measured high use of FQs given that recommendations and guidelines highlight the need for prudent FQ use and that these are not recommended as first-line treatment. This would be an indication of poor adherence to guidelines and recommendations. The study concludes by underlining that the excessive and inappropriate use of quinolones is not only associated with the development of resistance, but also higher costs for health providers and additional risk of adverse events for patients [21, 22, 45] .
Our survey showed that around half of current LRTI and CAP guidelines express the need for prudent FQ use, indicating them as the second drug of choice for treatment. We did not specifically look at the actual adherence to the guidelines or the actual use and prescription of FQs for these respiratory indications. However, the study by ADRIAENSSENS et al. [45] indicates that the use of FQs for outpatient care of lower respiratory infections is higher than warranted, indicating suboptimal adherence to guidelines.
Conclusion
The meta-analysis performed to assess whether treatment with FQs before the diagnosis of TB is associated with a higher risk of FQ-resistant TB suggests this is indeed the case. Whilst a number of national and sub-national guidelines on treatment of LRTI and/or CAP include the need to consider TB as a differential diagnosis and also the prudent use of FQs given the risk for FQ resistance, several guidelines are still lacking this consideration.
If the incidence of MDR-/XDR-TB, as well as TB resistant to all drugs, is to be curbed and decreased through enhanced control practices, it is essential to assure the rational use of drugs, not only for TB but also in other LRTIs. As countries reach the elimination phase of TB, the knowledge among healthcare workers will also change and, thus, the challenge lies in maintaining the know-how and awareness of TB, its diagnosis and its treatment. Therefore, reaching healthcare workers through other healthcare system channels becomes an important action as TB care becomes decentralised and national TB programmes become horizontal rather than vertical.
The measured increased risk for FQ resistance upon exposure to FQs in potentially misdiagnosed TB patients, as shown in this systematic review, highlights the urgency to further strengthen and adhere to national and sub-national guidelines to ensure this trend is interrupted.
The international community has just taken a breath after agreeing on the XDR-TB definition in 2006 and discussions have been initiated on how to define the most advanced levels of drug resistance [12] [13] [14] . Agreement on these definitions is complicated by the different panels of second-line drugs tested in different countries and laboratories and by the new drugs recently used to treat these difficult cases (e.g. linezolid) [46] . FQs are key drugs in the treatment of TB; FQ resistance is a XDR-TB defining marker and, even in MDR-TB cases which
are not yet XDR, it leads to worse prognosis (failure and death) [20] . In light of new anti-TB drugs predicted to become available within the next 2 yrs, the need to reinforce advocacy and training on the rational use of antibiotics is evident. PERSPECTIVE: PROTECTING THE TB DRUG PIPELINE G.B. MIGLIORI ET AL.
